`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Breaking:
`Polar Bears: Long Hungry Summer
`
`Science News
`
`from research organizations
`Drug shows surprising efficacy as treatment for chronic
`leukemia, mantle cell lymphoma
`
`Date:
`
`June 19, 2013
`
`Source:
`
`Ohio State University Medical Center
`
`Summary:
`
`Clinical studies suggest that the novel, targeted agent ibrutinib shows real potential is a
`safe, effective, treatment for adults with chronic lymphocytic leukemia and for patients with
`mantle cell lymphoma.
`
`Share:
`
` 194
`
` 57
`
` 4
`
` 2
`
`FULL STORY
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`1/8
`
`Exhibit 2005 Page 001
`
`Pharmacyclics LLC - Ex. 2005
`Coalition for Affordable Drugs IV LLC v. Pharmacyclics LLC
`Case IPR2015-01076
`
`
`
`John C. Byrd. Clinical results published online in NEJM show ibrutinib significantly prolongs survival in
`all classes of chronic lymphocytic leukemia (CLL) patients, even those at highrisk of recurrence;
`Similar results were shown in patients with mantle cell lymphoma (MCL).
`
`Credit: Image courtesy of Ohio State University Medical Center
`
`Two clinical studies published in the New England Journal of Medicine with an accompanying
`editorial suggest that the novel agent ibrutinib shows real potential as a safe, effective,
`targeted treatment for adults with chronic lymphocytic leukemia (CLL) and for patients with
`mantle cell lymphoma (MCL).
`
`Both studies, coled by researchers at the Ohio State University Comprehensive Cancer Center Arthur
`G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at MD
`Anderson Cancer Center, were published in the Journal's June 19, 2013 online edition.
`
`Chronic Lymphocytic Leukemia and Ibrutinib
`
`Results from this phase Ib/II trial showed an overall response rate (complete and partial) of 71 percent.
`At 26 months the estimated progressionfree survival rate was 75 percent and overall survival was 83
`percent.
`
`"Essentially all CLL patients respond well to ibrutinib, which lacks many of the side effects of
`chemotherapy and frequently produces longlasting remissions even in patients with highrisk genetic
`lesions," says study coleader John C. Byrd, MD, director of the division of hematology and a CLL
`specialist at the OSUCCC James.
`
`CLL is the most common form of leukemia with an estimated 15,000 Americans diagnosed annually. It is
`a cancer of B cells, which are a major component of the immune system along with T cells. Ibrutinib
`(PCI32765) is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLLcell
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`2/8
`
`Exhibit 2005 Page 002
`
`
`
`survival and proliferation. Ibrutinib kills malignant B cells but has little effect on healthy T cells unlike
`other CLL therapies. This leaves an important arm of the immune system largely intact, enabling patients
`to remain healthier during treatment.
`
`The trial involved 85 relapsed CLL patients (median age, 66) who took ibrutinib once daily. Fiftyone
`patients received a 420 mg dose and 34 patients received an 840 mg dose. Longterm therapy was
`associated with modest side effects such as diarrhea, fatigue, and infection that usually resolved with no
`treatment delay.
`
`Funding for the study was provided by Pharmacyclics, Inc.; the Leukemia and Lymphoma Society; D.
`Warren Brown Foundation; Mr. and Mrs. Michael Thomas; the Harry Mangurian Foundation; and the
`NIH/National Cancer Institute (grant CA140158 and CA095426).
`
`Mantle Cell Lymphoma and Ibrutinib
`
`Results from this phase II trial showed an overall response rate of 68 percent, with 21 percent of patient
`achieving a complete response and 47 percent achieving a partial response. Estimated overall survival
`was 58 percent at 18 months.
`
`"This is remarkable because the last agent approved by the Food and Drug Administration for MCL had
`a 30 percent response rate," says senior author Kristie Blum, MD, associate professor of medicine, and
`head of the OSUCCC James lymphoma program. "This trial suggests that ibrutinib could significantly
`improve the landscape of therapy options for MCL."
`
`MCL is a type of nonHodgkin lymphoma, a malignancy that is expected to strike nearly 70,000
`Americans in 2013. About 7 percent of those cases will be MCL, a cancer of white blood cells called B
`lymphocytes, or B cells. Currently, oncologists treat MCL using combination chemotherapy or intensive
`chemotherapy plus immunotherapy, followed by stemcell transplantation.
`
`The trial involved 111 patients with relapsed or refractory MCL who took ibrutinib. The trial was
`conducted at 18 sites. Participants had received one to five prior treatments, which could include the
`drug bortezomib, an agent sometimes used to treat MCL. The estimated median response duration was
`17.5 months and estimated median progressionfree survival was 14 months.
`
`Funding for the study was provided by Pharmacyclics, Inc.
`
`Story Source:
`
`The above post is reprinted from materials provided by Ohio State University Medical Center. Note:
`Materials may be edited for content and length.
`
`Journal References:
`
`1. Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer, Brad S. Kahl, Wojciech
`Jurczak, Ranjana H. Advani, Jorge E. Romaguera, Michael E. Williams, Jacqueline C. Barrientos,
`Ewa Chmielowska, John Radford, Stephan Stilgenbauer, Martin Dreyling, Wieslaw Wiktor
`Jedrzejczak, Peter Johnson, Stephen E. Spurgeon, Lei Li, Liang Zhang, Kate Newberry, Zhishuo Ou,
`Nancy Cheng, Bingliang Fang, Jesse McGreivy, Fong Clow, Joseph J. Buggy, Betty Y. Chang, Darrin
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`3/8
`
`Exhibit 2005 Page 003
`
`
`
`M. Beaupre, Lori A. Kunkel, Kristie A. Blum. Targeting BTK with Ibrutinib in Relapsed or
`Refractory MantleCell Lymphoma. New England Journal of Medicine, 2013; 130619140102001
`DOI: 10.1056/NEJMoa1306220
`2. John C. Byrd, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Jan A. Burger, Kristie A. Blum,
`Barbara Grant, Jeff P. Sharman, Morton Coleman, William G. Wierda, Jeffrey A. Jones, Weiqiang
`Zhao, Nyla A. Heerema, Amy J. Johnson, Juthamas Sukbuntherng, Betty Y. Chang, Fong Clow, Eric
`Hedrick, Joseph J. Buggy, Danelle F. James, Susan O'Brien. Targeting BTK with Ibrutinib in
`Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013;
`130619140102001 DOI: 10.1056/NEJMoa1215637
`
`Cite This Page:
`
`MLA
`
`APA
`
`Chicago
`
`Ohio State University Medical Center. "Drug shows surprising efficacy as treatment for chronic leukemia,
`mantle cell lymphoma." ScienceDaily. ScienceDaily, 19 June 2013.
`<www.sciencedaily.com/releases/2013/06/130619195217.htm>.
`
`Share This Page:
`
`194
`
`57
`
`2
`
`104
`
`RELATED TOPICS
`
`Health & Medicine
`
` Lymphoma
`
` Leukemia
`
` Diseases and Conditions
`
` Colon Cancer
`
` Lung Cancer
`
` Brain Tumor
`
`RELATED TERMS
`
` Hodgkin's lymphoma
`
` Lymphoma
`
` Delirium
`
` Adult stem cell
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`4/8
`
`Exhibit 2005 Page 004
`
`
`
` Stem cell
`
` Stem cell treatments
`
`Related Stories
`
`Combining Targeted Drug With Chemotherapy Offers Longer Life to BCell Cancer Patients
`May 30, 2015 — Because of the significant benefit found in combining the targeted drug ibrutinib with
`standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an
`interim ... read more
`
`Reasons for Ibrutinib Therapy Discontinuation in CLL
`Feb. 27, 2015 — About 10 percent of patients with chronic lymphocytic leukemia discontinued therapy
`with the Bruton tyrosine kinase inhibitor drug ibrutinib because of disease progression during clinical
`trials, ... read more
`
`Pill May Represent Promising Treatment for Stubborn Blood Cancers, Study Finds
`Mar. 10, 2014 — A pill that suppresses a key regulator of cancer growth may provide hope to relapsed
`leukemia and lymphoma patients running out of treatment options for their aggressive, treatment
`resistant disease, ... read more
`
`Study Confirms Target of Potent Chronic Leukemia Drug
`Dec. 19, 2013 — A new study helps confirm that a molecule targeted by the experimental drug ibrutinib
`is critical for the development of chronic lymphocytic leukemia, the most common form of adult ...
`read more
`
`Strange & Offbeat
`
`HEALTH & MEDICINE
`Futuristic Brain Probe Allows for Wireless Control of Neurons
`
`No Bones About It: Cannabis May Be Used to Treat Fractures
`
`Does Salt Cause Thirst? It's Really Not All That Certain
`
`Better Chocolate With Microbes: Same Yeast Used in Beer, Wine and Bread
`
`MIND & BRAIN
`
`The Emerging Science of Human Screams
`
`
`
`
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`5/8
`
`Exhibit 2005 Page 005
`
`
`
`The Emerging Science of Human Screams
`
`MemoryLoss Man Case 'Like Nothing We Have Ever Seen Before'
`
`Robotics and the Law: When Software Can Harm You
`
`Human Color Vision Gives People Ability to See Nanoscale Differences
`
`LIVING & WELL
`Misquotes and Memes: Did Ben Franklin Really Say That?
`
`When Times Are Tough, Parents Favor Daughters Over Sons
`
`Disgust Dampens Women's Sexual Arousal More Than Fear
`
`Conservatives Demonstrate More Self Control Than Liberals, Studies Suggest
`In Other News
`
`from NewsDaily
`
`SCIENCE
`Seattle's longbroken tunnelboring machine set to resume Nov. 23
`
`NASA scientist Claudia Alexander, last Galileo project manager, dies at 56
`
`Scientists puzzle over Pluto's polygons
`
`Aiyeeeee! Human screams jolt brain's fearresponse center
`
`No solace for fooddeprived polar bears as sea ice wanes
`
`HEALTH
`Ahead of Alzheimer’s meeting, researchers seize on signs of progress
`
`Requiring condom use in porn films gets enough signatures for California vote
`
`Rolling walkers ease outdoor walks for lung disease patients
`
`CVS Health's photo service, UCLA Health get hacked
`
`Few U.S. adults meet fruit, vegetable intake guidelines
`
`ENVIRONMENT
`California brush fire forces evacuation of more than 300 campers: fire officials
`
`Dozens flee homes as wildfires rage in Greece, PM urges calm
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`6/8
`
`Exhibit 2005 Page 006
`
`
`
`Quake measuring 6.9 magnitude sparks brief tsunami warning for Solomons
`
`In bid for Syngenta, Monsanto woos U.S. farmer support
`
`Montana train derailment spilled 35,000 gallons of crude oil
`
`TECHNOLOGY
`China central bank issues guidelines on internet finance development
`
`Regulators to seek penalty on Toshiba for false accounting: Nikkei
`
`Online gambling firm 888 wins $1.4 billion battle for Bwin.party
`
`Google gains billions in value as YouTube drives ad growth
`
`Exclusive: Uber, Lyft face disability access questions from Massachusetts
`
` Print Email Share
`
`Free Subscriptions
`
`Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or
`view hourly updated newsfeeds in your RSS reader:
`
` Email Newsletters
`
` RSS Feeds
`
`Follow Us
`
`Keep up to date with the latest news from ScienceDaily via social networks:
`
`
`
` Google+
`
`
`Mobile Apps
`
`Get the latest news from ScienceDaily via our free mobile apps, available for download on the following
`platforms:
`
` iPhone/iPad
`
` Android
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`7/8
`
`Exhibit 2005 Page 007
`
`
`
`Have Feedback?
`
`Tell us what you think of ScienceDaily we welcome both positive and negative comments. Have any
`problems using the site? Questions?
`
` Leave Feedback
`
` Contact Us
`
`About This Site | Editorial Staff | Awards & Reviews | Contribute | Advertise | Privacy Policy | Terms of
`
`Use
`
`Copyright 2015 ScienceDaily or by third parties, where indicated. All rights controlled by their respective
`owners.
`Content on this website is for information only. It is not intended to provide medical or other professional
`advice.
`Views expressed here do not necessarily reflect those of ScienceDaily, its staff, its contributors, or its
`partners.
`
`7/18/2015
`
`Drug shows surprising efficacy as treatment for chronic leukemia, mantle cell lymphoma ScienceDaily
`
`http://www.sciencedaily.com/releases/2013/06/130619195217.htm
`
`8/8
`
`Exhibit 2005 Page 008
`
`